Medications for Glioma
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Glioma.
Found 11 Approved Drugs for Glioma
Temodar
Generic Name
Temozolomide
Temodar
Generic Name
Temozolomide
Form: Injection, Capsule
Method of administration: Oral, Intravenous
FDA approval date: August 11, 1999
Classification: Alkylating Drug
Temozolomide capsules are an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment.
Bevacizumab
Brand Names
Zirabev, Jobevne, Avzivi tnjn, Avastin, MVASI, Avzivi, Vegzelma, Alymsys
Bevacizumab
Brand Names
Zirabev, Jobevne, Avzivi tnjn, Avastin, MVASI, Avzivi, Vegzelma, Alymsys
Form: Injection
Method of administration: Intravenous, Intravascular
FDA approval date: February 26, 2004
Classification: Vascular Endothelial Growth Factor Inhibitor
MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
Gliadel
Generic Name
Carmustine
Gliadel
Generic Name
Carmustine
Form: Kit, Wafer
Method of administration: Intravenous, Intracavitary
FDA approval date: December 13, 2012
Classification: Alkylating Drug
Carmustine for injection, USP is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. Carmustine for injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors Multiple myeloma-in combination with prednisone Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.
Aminolevulinic
Brand Names
Ameluz, Levulan Kerastick, Gleolan
Aminolevulinic
Brand Names
Ameluz, Levulan Kerastick, Gleolan
Form: Kit, Powder, Gel
Method of administration: Oral, Topical
FDA approval date: September 04, 2000
Classification: Optical Imaging Agent
Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. ( 1 )
Everolimus
Brand Names
Torpenz, Afinitor Disperz, Afinitor, Zortress
Everolimus
Brand Names
Torpenz, Afinitor Disperz, Afinitor, Zortress
Form: Tablet
Method of administration: Oral
FDA approval date: March 31, 2009
Classification: mTOR Inhibitor Immunosuppressant
TORPENZ (everolimus) tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
Showing 1-5 of 11
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances